Want to see SIGA full AI Analyst Report?
Top Page
SIGA Technologies
(NASDAQ:SIGA)
Select Model
Select Model
Rating:55Neutral
Price Target:
$3.00
▼(-3.54% Downside)
Action:Reiterated
Date:07/24/26
The score is held back primarily by unstable recent financial performance (extreme TTM net loss and steep revenue decline) and bearish technicals (price below key moving averages with negative MACD). These are partially offset by a strong balance sheet and cash position, positive though declining free cash flow, and an earnings call that provided near-term delivery guidance and demonstrated shareholder-friendly capital returns.
Positive Factors
Strong liquidity and zero net debt
A large cash balance with no debt provides durable financial flexibility: funds R&D and regulatory work, underpins multi-year runway despite lumpy orders, enables opportunistic M&A or commercial investment, and supports repeated special dividends without stressing operations.
Negative Factors
Sharp recent revenue decline and concentration risk
Material revenue contraction highlights dependence on episodic government orders and a concentrated customer base. Prolonged or repeated revenue declines would compress operating leverage, weaken pricing power in negotiations, and reduce predictability of cash flows needed to sustain R&D and commercialization investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong liquidity and zero net debt
A large cash balance with no debt provides durable financial flexibility: funds R&D and regulatory work, underpins multi-year runway despite lumpy orders, enables opportunistic M&A or commercial investment, and supports repeated special dividends without stressing operations.
Read all positive factors
SIGA Technologies (SIGA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$234.54M
Dividend YieldN/A
Average Volume (3M)461.52K
Price to Earnings (P/E)11.4
Beta (1Y)1.58
Revenue Growth-22.07%
EPS Growth-58.28%
CountryUS
Employees49
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.29
Shares Outstanding71,724,100
10 Day Avg. Volume376,632
30 Day Avg. Volume461,516
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)2.20
Price to Sales (P/S)4.62
P/FCF Ratio10.15
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.7
Revenue Forecast (FY)$66.31M
SIGA Technologies Business Overview & Revenue Model
Company Description
SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat hu...
How the Company Makes Money
SIGA primarily makes money by selling TPOXX (tecovirimat) to government customers and other public health preparedness buyers, with demand driven by biodefense stockpiling and outbreak response. The company’s revenue is largely product revenue fro...
SIGA Technologies Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Positive
The call presents a generally positive strategic and financial position driven by a strong cash balance, shareholder-friendly capital return, confirmed near-term international orders, regional commercial expansion via an exclusive Hikma agreement, and concrete pipeline progress (pediatric IND and PEP pathway). Offsetting these positives are the quarter's minimal deliveries and lumpy revenue profile, a small quarterly loss, a CHMP recommendation to withdraw the MPOXX indication in Europe, and slower progress toward a new U.S. government contract. Overall, the positives (liquidity, contracts, partnerships, and pipeline momentum) outweigh the near-term operational and regulatory headwinds.Positive Updates
Strong liquidity and balance sheet
Cash balance of approximately $146 million as of 03/31/2026 with no debt; pro forma cash would remain over $100 million after the special dividend, supporting runway and optional capital deployment.
Negative Updates
Quarterly revenue variability and minimal Q1 deliveries
First quarter had minimal product deliveries; Q1 product revenues included approximately $1 million of IV TPOXX deliveries to the SNS and about $2 million of reimbursement revenues, plus ~$3 million in R&D revenues — highlighting the lumpy, variable rhythm of the business.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong liquidity and balance sheet
Cash balance of approximately $146 million as of 03/31/2026 with no debt; pro forma cash would remain over $100 million after the special dividend, supporting runway and optional capital deployment.
Read all positive updates
Company Guidance
Management reiterated that results are lumpy and should be viewed over the long term, and guided Q2 product revenues to include approximately $13.0 million of oral TPOXX to an international customer plus additional IV TPOXX deliveries to the SNS; Q1 product revenues comprised roughly $1.0M of IV deliveries to the SNS and ~$2.0M of reimbursement related to manufacturing tech transfer, with ~$3.0M of R&D revenue. Financial metrics for the quarter ended 03/31/2026 included a pretax operating loss of ~ $5.0M, net loss of ~ $3.0M, and fully diluted loss per share of $0.05; the company had cash of ~ $146.0M, no debt, and declared a special cash dividend of $0.60 per share (declared March 26, record April 7, paid April 23). Pipeline and timing guidance: $27.0M of 2025 funding supports pediatric formulation and IV tech transfer work, a 2025 IV order was received, a pediatric IND was filed and a Phase 1 study is underway with results expected in H2 2026, CDC immunogenicity analysis for the PEP program is ongoing, and an FDA submission for the PEP indication is targeted within the next 12 months.SIGA Technologies Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
74
Positive
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 93.78M | 94.60M | 138.72M | 139.92M | 110.78M | 133.67M |
| Gross Profit | 61.29M | 64.87M | 107.43M | 122.09M | 100.34M | 117.07M |
| EBITDA | 27.50M | 30.96M | 76.61M | 88.31M | 44.65M | 89.83M |
| Net Income | 20.26M | 23.30M | 59.21M | 68.07M | 33.90M | 69.45M |
Balance Sheet | ||||||
| Total Assets | 219.39M | 219.47M | 244.34M | 254.35M | 195.04M | 214.73M |
| Cash, Cash Equivalents and Short-Term Investments | 145.56M | 154.97M | 155.40M | 150.15M | 98.79M | 103.14M |
| Total Debt | 638.23K | 595.17K | 546.82K | 564.01K | 528.17K | 466.83K |
| Total Liabilities | 67.77M | 20.65M | 28.53M | 57.49M | 24.88M | 40.41M |
| Stockholders Equity | 151.62M | 198.82M | 215.80M | 196.86M | 170.16M | 174.31M |
Cash Flow | ||||||
| Free Cash Flow | 27.42M | 43.12M | 48.72M | 94.78M | 41.61M | 11.44M |
| Operating Cash Flow | 27.75M | 43.47M | 48.76M | 94.80M | 41.61M | 11.49M |
| Investing Cash Flow | -330.12K | -355.01K | -42.45K | -21.69K | 0.00 | -50.62K |
| Financing Cash Flow | -44.12M | -43.55M | -43.46M | -43.42M | -45.96M | -26.20M |
SIGA Technologies Technical Analysis
Negative
3.11
Price Trends
3.87
Negative
4.20
Negative
5.05
Negative
Market Momentum
-0.19
Negative
34.89
Neutral
40.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SIGA, the sentiment is Negative. The current price of 3.11 is below the 20-day moving average (MA) of 3.36, below the 50-day MA of 3.87, and below the 200-day MA of 5.05, indicating a bearish trend. The MACD of -0.19 indicates Negative momentum. The RSI at 34.89 is Neutral, neither overbought nor oversold. The STOCH value of 40.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SIGA.
SIGA Technologies Risk Analysis
SIGA Technologies disclosed 37 risk factors in its most recent earnings report. SIGA Technologies reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SIGA Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $234.54M | 11.42 | 10.62% | ― | -22.07% | -58.28% | |
52 Neutral | $304.96M | -16.21 | -0.07% | ― | 12.19% | 1.97% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $372.53M | -42.47 | -1.59% | ― | -29.89% | 93.33% | |
47 Neutral | $463.60M | -6.06 | 190.87% | ― | -7.30% | -3.31% |
* Healthcare Sector Average
SIGA
SIGA Technologies
3.12
-4.44
-58.75%
EBS
Emergent Biosolutions
5.31
-2.93
-35.56%
ORGO
Organogenesis Holdings
2.41
-2.11
-46.68%
AQST
Aquestive Therapeutics
3.92
-0.01
-0.25%
SIGA Technologies Corporate Events
Executive/Board ChangesShareholder Meetings
SIGA Technologies Shareholders Approve Directors and Equity Plan
Neutral
Jun 10, 2026
SIGA Technologies’ stockholders met at the company’s 2026 Annual Meeting on June 9, 2026, with 87.05% of outstanding common shares represented in person or by proxy. Investors voted on board composition, auditor ratification, executive...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.